Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab B-cell depletion pilot study in amyotrophic lateral sclerosis
2022-502743-35-00Phase 2Authorised
- Sponsor
- German Center for Neurodegenerative Diseases
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Rituximab + riluzole with Placebo + riluzole (2 arms). Primary endpoint: Change in ALS Functional Rating Scale - Revised self-explanatory version. Planned start Apr 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2022-502743-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502743-35-00.